Navigation Links
Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Date:11/29/2007

">http://www.sec.gov. The proxy statement and these other documents, when available, may also be obtained free of charge from the Company by directing a request to the Company at 2 Snunit Street, Science Park, POB455, Carmiel, Israel 20100, Attention: Secretary.

In 2006, in accordance with the laws of the State of Florida, the Company did not deliver a proxy statement to its shareholders. Rather, all matters that required the approval of the Company's shareholders were submitted to the holders of a majority of interest of the Company's outstanding voting securities for written consents in lieu of a meeting. In planning for the 2007 Annual Meeting of Shareholders, the Company chose to hold the 2007 Annual Meeting of Shareholders after it had completed its planned public offering which was consummated on October 25, 2007. Accordingly, the Company determined to hold the 2007 Annual Meeting of Shareholders in early 2008 to allow for the orderly distribution of the proxy materials to its Shareholders.

The Company, its directors and named executive officers may be deemed to be participants in the solicitation of the Company's shareholders in connection with the 2007 Annual Meeting of Shareholders. Shareholders may obtain information regarding the names, affiliations and interests of such individuals in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as amended, and in the other filings by the Company with the SEC.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based expression system. Protalix's ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes is safe and scalable and will allow for the cost-effective, indust
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Protalix BioTherapeutics to Present at UBS Global Life Sciences Conference
2. Protalix BioTherapeutics Announces Public Offering of Common Stock
3. Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock
4. Protalix BioTherapeutics to Present at CIBC World Markets 18th Annual Healthcare Conference
5. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
6. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
7. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
8. Globus Medical Announces Record 2nd Quarter 2007 Results
9. BioSpace Draws Record Crowd to Chicago Life Science Career Fair
10. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
11. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014  Last week, Representatives Gus ... (D-NC) took a bold bipartisan step on behalf ... OPEN Act. Original co-sponsors of the legislation include ... will incentivize drug makers and innovators to "repurpose" ... pediatric cancers, which opens the door to the ...
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) ... trials at its mid-Atlantic late-phase research facility, located ... with the idea of closing patient disparities in ... medical advances," said Continental's CEO, Saleh Stevens ... immortal cell line of Henrietta Lacks, dubious ethical ...
(Date:11/23/2014)... 23, 2014 Apiscent Labs, a ... fine chemical ingredients to the global pharmaceutical and ... its new website, Apiscent.com. , The Apiscent.com homepage ... clean design, easy navigation, rotating images and content ... stand out. , The company’s work ...
(Date:11/22/2014)... November 21, 2014 RURO, Inc., ... provider, has released Limfinity® version 5.1.4. , RURO’s ... of Limfinity® than ever in RURO’s 8 year ... minority framework enhancement. Limfinity® version 5.1.4 is the ... and beyond bug fixes! , Limfinity® 5.1.4 release ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2
... Champions,Biotechnology, Inc. (OTC Bulletin Board: CSBR), a ... Dr. David,Sidransky, Director of the Head and Neck ... Medicine, to serve as Chairman of the Board,replacing ... since 1991. Dr.,Sidransky was appointed to serve on ...
... to customers in 2006, ALLERCA,s hypoallergenic cats have established a unique ... ... world., WILMINGTON, Calif., Oct. 23 ALLERCA, the company that,developed the ... first kitten deliveries to,eager customers. Since then, the company has delivered dozens ...
... of phase 2 breast cancer data show preferential, ... -- Results from 169 patients treated with adecatumumab ... apparent lack of immunogenicity of the antibody, ... ), a biopharmaceutical company focusing on the development of,novel, proprietary ...
Cached Biology Technology:Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 2Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 3Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 4One Year On, ALLERCA Hypoallergenic Cats Bring 'Sneeze Free' Companionship to Allergy and Asthma Sufferers 2One Year On, ALLERCA Hypoallergenic Cats Bring 'Sneeze Free' Companionship to Allergy and Asthma Sufferers 3Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 2Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 3Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 4Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 5
(Date:11/21/2014)... 2014 Strict laws against distracted driving and ... North American and European automotive sector towards gesture recognition ... systems that are intuitive and able to retrieve information ... New analysis from Frost & Sullivan,s ... Europe and North ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... the University of Minnesota will help corn and soybean farmers ... change. The project is funded by a five-year, $4.1 ... of Food and Agriculture (NIFA). The aim is to take ... in anticipation of climatic changes such as stronger storms and ...
... (July 6, 2011) A new animal study from Europe ... their newborn,s kidney development. Among the most significant aspects ... too little salt during pregnancy had an adverse effect on ... such disruption can lead to high blood pressure in later ...
... of the hidden dangers that may be lurking in our ... Europe are redevelopments of land that used to belong to ... can leave highly carcinogenic pollutants in the soil. There are ... and treated across Europe, according to EU estimates. Developers ...
Cached Biology News:U of M project will help corn and soybean farmers prepare for climate change 2A mother's salt intake could be key to prenatal kidney development 2A mother's salt intake could be key to prenatal kidney development 3Dealing with pollution James Bond style 2Dealing with pollution James Bond style 3
For cleavage of 6xHis tags from proteins containing a Factor Xa Protease recognition site Efficient 6xHis tag cleavage (greater than 90%), ...
HIV Reverse Transcriptase provides an excellent target for evaluating antiviral agents or catalyzing error prone synthesis on RNA and DNA templates....
supplied with 10x reaction buffer...
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
Biology Products: